• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma.

作者信息

Shackleton Louisa, Fay James, Smyth Elizabeth, Murphy Philip, Glavey Siobhan, Quinn John

机构信息

Department of Haematology Beaumont Hospital Dublin Ireland.

出版信息

EJHaem. 2020 Jul 4;1(1):312-314. doi: 10.1002/jha2.34. eCollection 2020 Jul.

DOI:10.1002/jha2.34
PMID:35847740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176006/
Abstract
摘要

相似文献

1
Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受达雷妥尤单抗单药治疗后肿瘤溶解综合征的实验室特征
EJHaem. 2020 Jul 4;1(1):312-314. doi: 10.1002/jha2.34. eCollection 2020 Jul.
2
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.达雷妥尤单抗用于初诊及复发/难治性多发性骨髓瘤的治疗：当前及新出现的疗法
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
3
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.达雷妥尤单抗单药治疗复发/难治性多发性骨髓瘤患者后的免疫调节剂药物和蛋白酶体抑制剂再治疗的疗效。
Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6.
4
Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.简要报告：达雷妥尤单抗单药疗法在实际临床中紧急用于复发或难治性多发性骨髓瘤后的临床经验
Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177.
5
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.EMA 对达雷妥尤单抗治疗多发性骨髓瘤成人患者的评估。
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
6
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.达雷妥尤单抗单药早期准入治疗方案在西班牙复发或难治性多发性骨髓瘤患者中的疗效
Hemasphere. 2020 Jun 3;4(3):e380. doi: 10.1097/HS9.0000000000000380. eCollection 2020 Jun.
7
Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.达雷妥尤单抗治疗复发/难治性多发性骨髓瘤中国患者的前瞻性、多中心、IV 期研究。
Future Oncol. 2024 Feb;20(4):191-205. doi: 10.2217/fon-2023-0842. Epub 2023 Dec 20.
8
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.达雷妥尤单抗单药治疗复发或难治性多发性骨髓瘤的真实世界中大量预处理患者的疗效。
Adv Med Sci. 2019 Sep;64(2):349-355. doi: 10.1016/j.advms.2019.05.001. Epub 2019 May 21.
9
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.皮下注射达雷妥尤单抗和透明质酸酶-fihj用于新诊断或复发/难治性多发性骨髓瘤
Ther Adv Hematol. 2021 Jan 22;12:2040620720987075. doi: 10.1177/2040620720987075. eCollection 2021.
10
Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review.达雷妥尤单抗在复发或难治性多发性骨髓瘤患者中的作用：一项荟萃分析及文献综述
J Family Med Prim Care. 2022 Jun;11(6):2648-2655. doi: 10.4103/jfmpc.jfmpc_1987_21. Epub 2022 Jun 30.

本文引用的文献

1
An upsurge of the serum free light chains as a possible missing link in tumour lysis syndrome in multiple myeloma.血清游离轻链升高可能是多发性骨髓瘤肿瘤溶解综合征的缺失环节。
Br J Haematol. 2020 Mar;188(5):732-735. doi: 10.1111/bjh.16231. Epub 2019 Oct 1.
2
Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab.
Eur J Case Rep Intern Med. 2017 Jan 27;4(1):000516. doi: 10.12890/2016_000516. eCollection 2017.
3
Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.卡非佐米诱发复发多发性骨髓瘤肿瘤溶解综合征：两例报告
Tumori. 2019 Dec;105(6):NP24-NP27. doi: 10.1177/0300891618793817. Epub 2018 Dec 23.
4
A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.1例与埃罗妥珠单抗治疗多发性骨髓瘤相关的肿瘤溶解综合征和急性肾衰竭病例。
Clin Nephrol Case Stud. 2017 Nov 22;5:78-81. doi: 10.5414/CNCS109165. eCollection 2017.
5
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未经治疗的多发性骨髓瘤。
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
6
High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.硼替佐米治疗的合并肾功能不全的有症状多发性骨髓瘤患者发生肿瘤溶解综合征的高风险。
Anticancer Res. 2016 Dec;36(12):6655-6662. doi: 10.21873/anticanres.11274.
7
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
8
Tumour lysis syndrome: new therapeutic strategies and classification.肿瘤溶解综合征：新的治疗策略与分类
Br J Haematol. 2004 Oct;127(1):3-11. doi: 10.1111/j.1365-2141.2004.05094.x.
9
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
Br J Haematol. 1999 Jun;105(4):938-41. doi: 10.1046/j.1365-2141.1999.01467.x.